{"prompt": "['2017N331008_0', 'CONFIDENTIAL', '208090', 'Participants with Grade >3 allergic reactions that are considered to be possibly or', 'probably related to the study intervention should permanently discontinue study', 'intervention and the participant should be withdrawn from the study. Participants should', 'be treated as clinically appropriate and followed until resolution of the AE.', '11.3.1.6. Rash', 'Mild to moderate rash is an expected adverse reaction for DTG-containing ART.', 'Episodes generally occur within the first ten weeks of treatment, rarely require', 'interruptions or discontinuations of therapy and tend to resolve within two to three weeks.', 'No instances of serious skin reaction, including SJS, TEN and erythema multiforme, have', 'been reported for DTG in clinical trials. For further characterisation of HSR and rash', 'observed with DTG-containing ART, please see the current version of the IB and any IB', 'supplements [GlaxoSmithKline Document Number RM2007/00683/11, GlaxoSmithKline', 'Document Number 2017N352880_00, GlaxoSmithKline Document Number', '2017N352880_01].', 'Participants with an isolated Grade 1 rash may continue study intervention at the', \"Investigator's discretion. The participant should be advised to contact the Investigator\", 'immediately if there is any worsening of the rash, if any systemic signs or symptoms', 'appear, or if mucosal involvement develops.', 'Participants may continue study intervention for an isolated Grade 2 rash. However,', 'study intervention (and all other concurrent medication(s) suspected in the Investigators', 'causality assessment) should be permanently discontinued for any Grade >2 rash that is', 'associated with an increase in ALT. The participant should be advised to contact the', 'physician immediately if rash fails to resolve (after more than two weeks), if there is any', 'worsening of the rash, if any systemic signs or allergic symptoms develop, or if mucosal', 'involvement develops.', 'Participants should permanently discontinue study intervention [and all other concurrent', 'medication(s) suspected in the Investigators causality assessment] for an isolated Grade', '3', 'or 4 rash, except where the aetiology of the rash has been definitively diagnosed as NOT', 'attributable to study intervention (see below), and the participant should be withdrawn', 'from the study. Participants should be treated as clinically appropriate and followed until', 'resolution of the AE. Every effort should be made to collect as much information as', 'possible about the evolution of the event and any relationship with potentially related', 'medical events (e.g., viral infection) or start of concomitant medication.', 'The rash and any associated symptoms should be reported as adverse events and', 'appropriate toxicity ratings should be used to grade the events (based on DAIDS toxicity', 'gradings, Section 11.10.', 'However, if the aetiology of the rash has been definitively diagnosed as being unrelated', 'to study intervention and due to a specific medical event or a concomitant infection or a', 'concomitant non-study medication, routine management should be performed and', '96']['2017N331008_06', 'CONFIDENTIAL', '208090', 'documentation of the diagnosis provided. In this situation, the study intervention should', 'be continued.', '11.3.1.7. Hypertriglyceridemia/Hypercholesterolemia', 'Samples for lipid measurements must be obtained in a fasted state according to the', 'Schedule of Activities (Section 1.3). Participants who experience asymptomatic', 'triglyceride or cholesterol elevations may continue to receive study intervention.', 'REFERENCE:', 'Inker LA, Schmid CH, Tighiouart H, et al; Estimating Glomerular Filtration Rate from', 'Serum Creatinine and Cystatin C. N Engl J Med. 2012;367:20-9.', 'Levey AS, Stevens LA, Schmid CH, et.al. A new equation to estimate glomerular', 'filtration rate. Ann Int Med. 2009; 150:604-12.', '97']\n\n###\n\n", "completion": "END"}